Movement Disorder Tests We Offer
The MNG portfolio of comprehensive and targeted next-generation sequencing (NGS) panels offers a complete set of molecular diagnostic tests to diagnose movement disorders. These NGS panels include testing for repeat expansions, single-exon resolution copy number variation (CNV), single-nucleotide variants (nuclear and mitochondrial), and mitochondrial genome deletions.
Our Comprehensive Ataxia panel features a robust selection of genes clinically relevant to ataxia. To provide you and your patients a high degree of clinical sensitivity testing, we also provide Friedreich Ataxia and Huntington’s Disease repeat expansion testing in conjunction with or separately from the next-generation sequencing panel. Moreover, select ataxia panels include complimentary Spinocerebellar Ataxia repeat expansion testing.
For dystonia phenotypes, we offer a Comprehensive Dystonia panel, which also includes complimentary mtDNA sequencing with deletion analysis. For a more targeted approach, we offer early-onset Primary Dystonia and OXPHOS Defect Dystonia panels.
Parkinson's Disease Testing
Parkinson’s disease affects more than 4 million people worldwide. In the United States alone, more than 60,000 people will be diagnosed with Parkinson’s disease this year.1 Though primarily a movement disorder, the progressive neural degeneration caused by Parkinson’s results in a wide-range of neurological symptoms ranging from dementia, anxiety, and depression.1 Our Parkinson’s Disease/Parkinsonism panel is designed to target Parkinson’s disease and other disorders that have partially overlapping symptomatology to ensure accuracy and sensitivity in the diagnosis for your patients.